PatientsVille.com Logo

Breast and Atenolol

PatientsVille

Breast Symptoms and Causes

Most women experience Breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not Breast milk).

If you have a Breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious Breast problems have similar symptoms. Although many women fear cancer, most Breast problems are not cancer.

Some common Breast changes are

  • Fibrocystic Breast changes - lumpiness, thickening and swelling, often just before a woman's period
  • Cysts - fluid-filled lumps
  • Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women
  • Intraductal papillomas - growths similar to warts near the nipple
  • Blocked milk ducts
  • Milk production when a woman is not Breastfeeding

NIH: National Cancer Institute

Check out the latest treatments for breast

breast treatment research studies

Atenolol clinical trials, surveys and public health registries


Find Drug Side Effect reports



Atenolol Side Effects

Bradycardia (333)
Dizziness (236)
Hypotension (218)
Completed Suicide (205)
Dyspnoea (180)
Nausea (171)
Blood Pressure Increased (150)
Syncope (145)
Hypertension (141)
Asthenia (141)
Fatigue (124)
Diarrhoea (124)
Headache (118)
Pain (115)
Malaise (110)
Toxicity To Various Agents (108)
Chest Pain (107)
Fall (98)
Palpitations (93)
Cerebrovascular Accident (89)
Vomiting (87)
Insomnia (81)
Myocardial Infarction (79)
Anxiety (78)
Oedema Peripheral (76)
Off Label Use (75)
Depression (75)
Pruritus (74)
Feeling Abnormal (73)
Back Pain (69)
Pain In Extremity (67)
Renal Failure Acute (66)
Abdominal Pain (66)
Arthralgia (66)
Weight Decreased (63)
Cough (62)
Heart Rate Increased (58)
Muscle Spasms (58)
Rash (58)
Blood Creatinine Increased (57)
Pneumonia (54)
Hyperkalaemia (54)
Loss Of Consciousness (53)
Overdose (53)
Weight Increased (53)
Hyperhidrosis (52)
Blood Cholesterol Increased (51)
Heart Rate Decreased (50)
Renal Failure (50)
Somnolence (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

8-)Have been taking atenolol and lisinipril for about 6 years, and before now did not realize the extreme itchiness in toes and fingers that started at first and now has turned in very cold and numb toes and feet and getting worse. I now believe it

Anxiety, Paranoia, Arrythmia

Before I took atenolol i had a perfect glucose numbers after taking it I came down with diabetes. I am 102lbs, 4'11, have always eaten healthy, exercise my whole life. I am 76. I was taken off atenolol after5 years...and NO ONE in my family for ge

Ben ongerust, vorig jaar zijn er Nagor implantaten vervangen door Allergan implantaten. De Nagor implanten waren gescheurd. Hoop maar dat dit geen gevolgen heeft voor mijn gezondheid. De Nagor implanten waren overigens al heet 2e stel, want het 1e s

Buenas quisiera saber si venden el medicamento rapamude o sirolimus en jarabe de 120 ml quisiera saber el costo,espero pronta respuesta muchas gracias

Congested chest

Has anyone else suffered from Atenelol induced Asthama and Bronchitis?

I have certain days of fatigue and I have constant chest congestion. How much can be attributed to the Atenolol or to my medical condition (atrial fibrulation)--I do not know.

I was started on atenolol for anxiety to stop the adrenilin, my bp was just a little elevated 150-100 during paniac attack. Will this drug work for anxiety?

I was told by increasing Atenol to 100 mg the pos. side effect was it protected your eyes from diabetes is this true on Your Mind?

i had suffering asthma since abaut 15 years. but since use seretide inhaler i am feeling more better. but i am affraid seretide inhaler 125 mg for along time. now iam still breast feeding for my third baby. and also iam affraid also increase m

Afer five years of Famera treatment for breast cancer, I was anticipating feeling so much better. Now diagnosed with CFS and Fibromyalgia my doctor is trying to treat me lately with Chronic Behavorial Therapy. Yesterday my daughter took me to another

Age 58, stage 1 breast cancer a year ago. double mastecomy, by choice. chemo...started aromasin in October 2008. had a bone denstity test in September 2008 and started fosamax.... had another bone denstity test in April 2009 and before the results

Am almost 60. Breast cancer survivor of 9 yrs. Taking Evista several years with no problems till Dec. 2010 . Now it's mid-March 2011. Severe shoulder pain, right shoulder. Tried stopping meds for one week. Resumed and pain increased within 7 hours. H

An herb can't give someone breast cancer. But I'm sorry for your loss.

Been prescribed endone after breast recontruction (lost breast to cancer several mths ago) It made me feel sick, had headaches and a very itchy skin rash. Took myself off them and now on nurofen +, much better.

Breast hurts,feeling moody,sings late at night

Breast pain

Breast pain on Premique for two weeks now, will this subside as the weeks go on?

Can it be a side effect of Solian if I had MASTYTIS (inflammation of breast) recently and rather much matter evacuated? I have been using Solian for about 8 - 9 months. My diagnosis is smth. schizotypical & depressive. Besides, I have been taking

Breast Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: whole Breast irradiation
Outcome Measures: Local recurrence defined as histologic evidence of ductal carcinoma in situ or invasive Breast cancer in the ipsilateral Breast or chest wall assessed up to 5 years;   Conversion rate to mastectomy secondary to persistent positive margins assessed;   Type and severity of adverse effects of Breast-conserving surgery and radiation as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Radiation-related side effects of whole-Breast radiation with a boost to 1 large or > 1 lumpectomy site as assessed by NCI CTCAE version 4.0;   Patient's perception of cosmesis assessed up to 24 months after WBI using the Breast-Q© scoring module
2 Recruiting Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Prophylactic radiation to the contralateral Breast
Outcome Measures: Rate of contralateral Breast cancer in carrier patients that received prophylactic radiation to the contralateral Breast compared with carrier patients that did not receive that treatment.;   Short and long term adverse effects of prophylactic contralateral Breast irradiation.;   factors that influence patient's choice of treatment
3 Not yet recruiting Trial of Two Electric Breast Pumps in Mothers of Term Infants.
Conditions: Volume of Breast Milk Expressed Using Single Electric Breast Pumps.;   Duration of Exclusive Breast-feeding;   Duration of Any Breast-feeding
Interventions: Device: Electric Breast pump - A;   Device: Electric Breast pump - B
Outcome Measures: The total weight of milk expressed in a set 20 minute period (10 minutes / Breast);   Exclusive and partial Breast-feeding
4 Recruiting Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer
Conditions: Breast Cancer;   Lumpectomy
Interventions: Radiation: Whole Breast Irradiation + Boost or Hypofractionated irradiation;   Radiation: Accelerated partial Breast irradiation
Outcome Measures: rate of local recurrence;   Ipsilateral Breast recurrence-free survival;   Nodal regional recurrence-free survival;   Distant recurrence-free survival;   Disease-specific survival;   Overall survival;   Toxicities: Measurement of the rate and type of toxicity (acute and late toxic effects);   Cosmetic: comparison of the cosmetic result (according to both the physician and the patient);   Quality of Life and Satisfaction;   Medico-economic study
5 Recruiting Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment
Condition: Breast Cancer
Interventions: Procedure: Reconstruction with ADM.;   Procedure: Skin or nipple sparing mastectomy;   Procedure: Reconstruction with implant;   Procedure: Total submuscular coverage;   Procedure: Partial submuscular coverage
Outcome Measures: The primary endpoint of this study is number of unplanned/ unanticipated surgical Breast procedures. Other endpoints in the trial will be secondary.;   Aesthetic outcome;   Complications;   Number of surgical procedures;   Cost-Benefit analysis;   Quality of Life
6 Recruiting Simulated Screening Study for Breast Imaging
Conditions: Breast Cysts;   Breast Abnormalities;   Breast Tumors
Intervention: Procedure: Imaging modalities for Breast cancer screening
Outcome Measures: Evaluation of new Breast imaging devices;   Determining the ratio of "patient call backs"
7 Recruiting Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
Condition: Breast Cancer
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC
Outcome Measures: Frequency of dose limiting adverse events.;   Immune response rate as measured by the number of IFN-gamma producing cells/well in a direct ELIspot assay of PBMCs collected at 30 days from the last peptide + poly-ICLC vaccination.;   The number of serious adverse events from the time of enrollment as defined by CTCAEv4.03;   Characterize responding peripheral CD8+ T-cell specificity by tetramer staining and measure by standardized flow cytometric criteria at 30 days post vaccine.;   The CD8+ T-cell activation as measured by cytokine bead assay upon peptide stimulation at 30 days from last vaccine.;   The frequency of immune responses among patients treated with anti-estrogen therapies
8 Recruiting Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts
Condition: Breast Cancer
Interventions: Device: Digital Breast Tomosynthesis;   Device: Automated Whole Breast Ultrasound;   Device: Full Field Digital Mammography
Outcome Measures: Abnormal interpretation rate;   Sensitivity;   Specificity;   Cancer Rate;   Positive Predictive Value;   Negative Predictive Value
9 Recruiting Efficacy of Single Stage Breast Reconstruction
Condition: Mastectomy and Breast Reconstruction
Interventions: Procedure: Breast reconstruction, direct to implant with Strattice;   Procedure: Two stage Breast reconstruction
Outcome Measures: Number of planned and unplanned post-mastectomy surgical interventions per subject;   Number of Breast-reconstruction related surgical complications
10 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole Breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
Outcome Measures: Rate of pCR in the Breast and post therapy lymph nodes;   Rate of pCR in the Breast;   RFI;   OS;   Rate of second primary invasive cancer of any type;   Patterns of pCR by menopausal status;   Patterns of RFI by menopausal status;   Patterns of OS by menopausal status;   Incidence of cardiac toxicity categorized according to National Cancer Institute CTCAE version 4.0;   Change in endocrine-related symptoms using Breast Cancer Prevention Trial (BCPT) symptom checklist;   Change in greater vasomotor symptoms, musculoskeletal complaints, and vaginal problems, as measured by the subscale scores from the BCPT symptom checklist;   Change in QOL as measured by the Functional Assessment of Cancer Therapy-Breast Trial Outcome Index (FACT-B TOI) and the 12-item Short Form (SF-12) Physical Component Scale (PCS)
11 Recruiting Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Condition: Breast Cancer
Interventions: Radiation: accelerated partial Breast irradiation - 3D-conformal planning;   Radiation: accelerated partial Breast irradiation - IMRT planning
Outcome Measures: Prevalence of Breast pain after Accelerated Partial Breast Radiotherapy (APBI);   Prevalence of chest wall pain after Accelerated Partial Breast Radiotherapy (APBI);   Dosimetric comparison;   Acute skin reactions;   Cosmetic outcomes after APBI;   Ipsilateral Breast tumor recurrence;   Cause specific survival;   Disease free survival;   Overall survival
12 Recruiting Partial Breast Versus Whole Breast Irradiation in Elderly Women Operated on for Early Breast Cancer
Condition: Breast Carcinoma
Interventions: Radiation: Partial Breast irradiation;   Radiation: Whole Breast irradiation
Outcome Measures: Grade 2 and/or 3 fibrosis after radiotherapy;   Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival
13 Recruiting Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
Condition: Breast Cancer
Interventions: Other: physiologic testing;   Other: screening questionnaire administration;   Procedure: Breast imaging study;   Procedure: radiomammography;   Procedure: study of high risk factors
Outcome Measures: Within-individual mammographic density (MD) longitudinal change and Breast cancer risk;   Patterns of within-individual longitudinal change in MD;   Predictors of across-individual differences in MD change
14 Unknown  Radiation Therapy in Treating Women With Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery
Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Outcome Measures: Local tumor control in the ipsilateral Breast (i.e., true recurrence plus new primary tumor) as confirmed by cytological or histological assessment;   Location of tumor relapse;   Contralateral primary Breast cancer or other primary tumors as confirmed by cytological or histological assessment;   Regional and distant metastases;   Late adverse effects in normal tissues as determined periodically by photographic assessments (in a subset of patients), physician assessments, and patient self-assessments;   Quality of life as assessed by EORTC QLQ C-30, EORTC QLQ-BR23, BIS, and HADS questionnaires in a subset of patients at baseline, 6 months, and 1, 2, and 5 years;   Cost-effectiveness as assessed by EQ-5D questionnaire at baseline, 6 months, and 1, 2, and 5 years
15 Recruiting Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
Conditions: Atypical Ductal Breast Hyperplasia;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ
Interventions: Dietary Supplement: curcumin;   Other: Biomarker analysis;   Other: Assessment of Dietary Intake;   Other: Daily Log
Outcome Measures: Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin (NEC)in women at high risk for developing Breast cancer.;   Evaluate possible correlations between physical factors such as body mass (BMI), dietary intake and pro-inflammatory effects in plasma and Breast adipose tissue.
16 Recruiting Partial Breast Proton Therapy for Early Stage Breast Cancer
Conditions: Breast Cancer;   Early Stage
Intervention: Radiation: Proton Beam Radiotherapy
Outcome Measures: Rate of recurrence in the Breast;   Disease free survival;   Complication rate in the Breast, chest wall and skin;   Rate of Breast recurrence of low versus intermediate risk patients
17 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic Breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
Outcome Measures: Progression Free Survival (PFS) for triple negative metastatic Breast cancer subjects (Phase 2);   Progression Free Survival (PFS) for triple negative metastatic Breast cancer subjects (Phase 3);   Investigator-determined Overall Response Rate (ORR) for triple negative metastatic Breast cancer subjects (Phase 2);   Percentage of triple negative metastatic Breast cancer subjects who initiated Cycle 6 (Phase 2);   Investigator determined Overall Survival (OS) for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 2);   Safety for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 2);   Independent blinded radiologists-determined Overall Response Rate (ORR) for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3);   Overall Survival (OS) for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3);   Compare disease control rate for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3);   Duration of Response for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3);   Safety of each treatment regimen for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3);   Investigator assessed Progression Free Survival (PFS)for triple negative metastatic Breast cancer (TNMBC) subjects (Phase 3)
18 Recruiting Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions
Conditions: Metastatic Breast Cancer;   Lung Metastases;   Liver Metastases
Intervention: Biological: anti-OX40 antibody
Outcome Measures: Determine the maximum tolerated dose and safety profile of radiation administered in combination with anti-OX40 in patients with metastatic Breast cancer.;   Estimate the response rate of combined modality treatment in both irradiated and non-irradiated tumors.
19 Recruiting Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions
Condition: Breast Neoplasms
Intervention: Device: Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner
Outcome Measures: Receiver Operative Curve (ROC) Area Under the Curve (AUC) (percentage);   Reader preference - arbitrary units
20 Unknown  MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery
Condition: Breast Cancer
Intervention: Procedure: Breast MRI
Outcome Measures: To determine whether pre-lumpectomy Breast MRI reduces the frequency of repeat lumpectomy in women with DCIS < 5 cm or T1 or T2 invasive Breast cancer;   To determine how often MRI will detect occult multifocal or multicentric disease;   To determine how often MRI will miss occult DCIS or invasive cancer subsequently detected on surgical pathology;   To determine the frequency with which Breast MRI changes the surgical plan;   To determine the frequency of false positive MRI findings requiring biopsy;   To measure whether MRI reduces the frequency of repeat lumpectomy to a greater extent in women with mammographically dense vs fatty Breasts;   To measure whether preoperative MRI is associated with enhanced postoperative cosmesis;   To measure whether preoperative MRI alters cost of care;   To measure the degree and extent to which preoperative MRI lengthens the time required to deliver care;   To measure whether preoperative MRI increases the rate of patient directed ("unnecessary") mastectomy;   To measure whether MRI decreases the risk of ipsilateral Breast tumor recurrence;   To measure disease-free survival without/with preoperative Breast MRI;   To measure overall survival without/with preoperative MRI